Icecure Medical Ltd

IceCure Medical faces a Nasdaq $1 bid‑price notice while gearing up to release Q3 2025 results; investors watch the company’s cryo‑ablation tech and financials for a stock‑price recovery.

Icecure Medical Ltd is a leader in minimally-invasive cancer treatment, utilizing liquid nitrogen to destroy tumors without surgery, and advancing patient care through innovative medical devices.